DOCSLIB.ORG
Explore
Sign Up
Log In
Upload
Search
Home
» Tags
» Rolapitant
Rolapitant
Fosaprepitant Dimeglumine (Emend® for Injection) Prior Authorization Drug Coverage Policy
MASCC/ESMO ANTIEMETIC GUIDELINE 2016 with Updates in 2019
Deciphering Emesis
Rolapitant Improves Quality of Life of Patients Receiving Highly Or Moderately Emetogenic Chemotherapy
HHS Template for Reports, with Instructions
Safety of HTX-019 (Intravenous Aprepitant) and Fosaprepitant in Healthy Subjects
VARUBI™ (Rolapitant) Tablets, for Oral Use Initial U.S
Rolapitant in the Current Management of Chemotherapy-Induced Nausea and Vomiting
The Significance of NK1 Receptor Ligands and Their Application In
Ehealth DSI [Ehdsi V2.2.2-OR] Ehealth DSI – Master Value Set
Varubi (Rolapitant)
Changes Highlighted Final Version Date of Issue: 23Rd December 2015
206500Orig1s000
Varuby, INN-Rolapitant
AWMSG Secretariat Assessment Report Rolapitant (Varuby®) 90 Mg Film-Coated Tablet
Helsana Arzneimittelreport 2019
Neurokinin Receptor NK Receptor
Varuby, INN-Rolapitant
Top View
Drug Consumption at Wholesale Prices in 2017 - 2020
Varubi) Reference Number: CP.PMN.102 Effective Date: 02.01.17 Last Review Date: 02.21 Coding Implications Line of Business: HIM, Medicaid Revision Log
Effects of Rolapitant on Nausea/Vomiting in Patients With
Risk Assessment and Risk Mitigation Review(S)
Neurokinin-1 (NK1) Receptor Antagonists and Combinations
Varubi™ (Rolapitant) — New Drug Approval
In Confidence Issues
Responding to the Challenge of Chemotherapy-Induced Nausea and Vomiting
Reference ID: 4658075 FULL PRESCRIBING INFORMATION
Akynzeo Injection (Fosnetupitant Palonosetron), Cinvanti, Emend (Aprepitant), Emend Injection (Fosaprepitant), Varubi (Rolapitant)
Patent Application Publication ( 10 ) Pub . No . : US 2019 / 0231688 A1
Rolapitant Is a Reversible Inhibitor of CYP2D6
ATC-Index Mit DDD-Angaben Für Deutschland Im Jahre 2018
A17-26 Rolapitant (Prevention of Nausea and Vomiting in Chemotherapy) – Benefit Assessment According to §35A Social Code Book V1
Klasifikacija ATC 2019
Lääkeluettelon Aineet, Liite 1. Ämnena I
New Therapies for Antiemetic Prophylaxis for Chemotherapy
Adult Antiemetic Management of Chemotherapy-Induced Nausea
ATC-Index Mit DDD-Angaben Für Deutschland Im Jahre 2019
Overview of the Neurokinin-1 Receptor Antagonists
Varubi® Common Name: Rolapitant PDL Category: Antiemetic Agents
Nausea and Vomiting SUPPORTIVE CARE BOOK SERIES
Guidelines for ATC Classification and DDD Assignment 2021
Drug Policy: Emend™ (Aprepitant Oral Or Fosaprepitant), Cinvanti™ (Aprepitant Injection), and Varubi™ (Rolapitant Oral)
The Use of Stems in the Selection of International Nonproprietary Names (INN) for Pharmaceutical Substances
WO 2017/060488 Al 13 April 2017 (13.04.2017) P O PCT
Recent Developments in the Clinical Pharmacology of Rolapitant: Subanalyses in Specific Populations
[Ehdsi V3.0.0-RC1] Ehealth DSI – Master Value Set Catalogue
Klasifikacija ATC 2021
SUOMEN LÄÄKETILASTO S LT FINNISH STATISTICS on MEDICINES FSM 8 Keskeisiä Lukuja Lääkkeiden Myynnistä Ja Lääkekorvauksista Vuonna 2018
Antiemetics for Oncology – Commercial Medical Benefit Drug
Management Chemotherapy and Radiotherapy Induced Nausea and Vomiting
Efficacy and Safety of Rolapitant for Prevention of Chemotherapy
CHEMOTHERAPY Rolapitant—A New and Safer Antiemetic Agent Chemotherapy-Induced Nausea and Vomiting (CINV) Is One of the Most Feared Adverse Effects of Chemotherapy
Varubi (Rolapitant)
A History of Drug Discovery for Treatment of Nausea and Vomiting and the Implications for Future Research
Antiemetic Therapy
FDA Approves Rolapitant for Chemotherapy- Induced Nausea and Vomiting
Varubi® (Rolapitant) Intravenous
Fourth Consensus Guidelines for the Management
ADAP Quarterly NDC Special Review